Introduction: Mushrooms are known for their immune modulating effect for which the polysaccharide fraction, mainly glucans, seem to be responsible. Fungal b-glucans have been studied extensively, whereas little is known about mushroom a-glucans. We have earlier shown that the polysaccharide fraction from the mushroom A. bisporus, consisting 90% of a-glucans, induced in vitro tumor necrosis factor (TNF)a and nitric oxide production. The purpose of this study was to evaluate the effects of consuming. Method: A. bisporus a-glucan on ex vivo cytokine production by human peripheral mononuclear blood cells (PBMCs). A doubleblind randomized trial was designed in which 56 mildly hypercholesterolemic subjects consumed a control fruit juice with no added a-glucans (200 ml/day) for a 2-week run-in period. For the next 5 weeks, the control group (N ¼ 30) continued consumption of the control fruit juice, whereas the intervention group (N ¼ 26) consumed the same fruit juice enriched with a-glucans from A. bisporus (5 g glucans/day). Changes in interleukin (IL)-1b, IL-6 and TNFa cytokine production by lipopolysaccharide (LPS)-stimulated PBMCs were evaluated, as well as changes in T-helper (Th)1/Th2 cytokines by phytohemaggutinin (PHA)-stimulated PBMCs. Results: Consumption of A. bisporus a-glucans lower LPS-induced TNFa production by 69% (P ¼ 0.017) as compared with the control group, whereas no effect on IL-1b and IL-6 was observed. No obvious Th1-Th2 skewing by PHA-stimulated PBMCs was observed. However, we observed a trend towards a decreased production of IL-12 and IL-10. Conclusion: Our current finding suggests that in vivo, a-glucans have lost their efficacy to stimulate the immune response as observed in our in vitro mouse model.
Introduction
Mushrooms have been studied extensively for their immunemodulating and anti-tumor properties (Brown et al., 2003; Borchers et al., 2004; Lull et al., 2005; Chen and Seviour, 2007; . Indeed, there are many potentially biologically active compounds present in mushrooms, for example, small proteins, lectins, polyphenols and polysaccharides. It is assumed that the polysaccharides are a main bioactive part of the mushrooms, at least in relation to their immune-modulating effects (Wasser, 2002) . These polysaccharides are mainly b-glucans that are present in the cell walls. In addition, also a-glucans are present in the polysaccharide fraction of mushrooms (Zhang and Cheung, 2002) . Whereas the effects of b-glucans have been studied extensively, little is known about the immune-modulating effect of mushroom a-glucans. We have reported earlier that a polysaccharide fraction from Agaricus bisporus, which contained 90% a-glucan increased nitric oxide and tumor necrosis factor (TNF)a production by bone marrow-derived macrophages from mice in vitro (Volman et al., 2009) . Furthermore, Bittencourt et al. (2006) have reported that a-glucans from Pseudallescheria boydii stimulated the in vitro secretion of TNFa and interleukin (IL)-12 by mice macrophages and dendritic cells. This increased secretion of IL-12 indicates a polarization of naive T-cells into T-helper (Th) type 1 skewed responses, which is generally attributed to mushroom b-glucans (Suzuki et al., 2001; Saito et al., 2003; Lin et al., 2006; Takimoto et al., 2008) . In addition, animal studies have also shown that consumption of A. bisporus stimulated the immune response (Wu et al., 2007; Ren et al., 2008) , but the bioactive fraction from these extracts is not known. It is possible that these immune-modulating effects were due to A. bisporus-derived a-glucans extracts, which have been studied to some extent in vitro and in animals. Effects of consuming these extracts on ex vivo cytokine production by isolated and stimulated human peripheral mononuclear blood cells (PBMCs) have, however, to the best of our knowledge, not been studied in well-controlled human trials. Therefore, the purpose of this study was to evaluate PBMC cytokine secretion patterns after consumption of a-glucan rich fractions from A. bisporus incorporated into fruit drinks in humans. For this, PBMCs were isolated and stimulated ex vivo by two approaches. First, we measured IL-1b, IL-6 and TNFa production after lipopolysacccharide (LPS) stimulation and secondly we evaluated a potential shift in the Th1/Th2 balance of secreted cytokines (IL-2, IL-4, IL-5, IL-12, IL-13, IL-17 and interferon (IFN)-g) after phytohemagglutinin (PHA) induced T-cell proliferation of isolated PBMCs.
Methods

Subjects
Fifty-six apparently healthy men and women with slightly elevated serum total cholesterol concentrations (between 6.0-8.0 mmol/l) were included in this study. Volunteers were recruited from Maastricht and surrounding villages by advertisements in local newspapers. In addition, subjects who had participated in earlier studies at our department were approached. Inclusion criteria were stable body weight (weight gain or loss o3 kg in the past 3 months); Quetelet index o32 kg/m 2 ; systolic blood pressure o160 mm Hg and diastolic blood pressure o95 mm Hg; no presence of glucosuria, proteinuria or anemia; no use of medication or a prescribed diet known to affect lipid or glucose metabolism; no history of coronary heart disease, cancer, diabetes, kidney, liver, pancreatic disease or malignancies o5 years ago; no abuse of drugs and/or alcohol; and no pregnant or breast-feeding women, serum triacylglycerol concentrations o3.0 mmol/l and serum total cholesterol concentrations between 6.0 and 8.0 mmol/l. Baseline characteristics are shown in Table 1 . There were no statistical differences between the two groups in these baseline characteristics. The subjects were requested not to change their habitual diets, levels of physical exercise, smoking habits or use of alcohol during the study. Blood donation or participation in another biomedical trial was not allowed 30 days before the start and during the study. The Medical Ethical Committee of the University of Maastricht approved the study and all subjects gave written informed consent before entering the study. Eight subjects dropped out during the study-all during the run-in period-because of various reasons not related to the experimental products, for example, holidays, difficulties during venipunctures.
Study design
The study had a placebo-controlled, double-blind, parallel design. Before the study started, all 56 subjects were randomly divided into two groups. During the first 2 weeks of the study (run-in period), all subjects consumed a fruit juice (200 ml/day) without added a-glucans from A. bisporus. The 200 ml was consumed at two occasions divided over the day, that is, ± 100 ml around lunch and ± 100 ml around dinner. During the following 5 weeks intervention period, the control group (N ¼ 30) continued consumption of the control fruit juice, whereas the intervention group (N ¼ 26; a-glucan group) consumed the same fruit juice but now enriched with a-glucans from A. bisporus (A. bisporus juice providing 5 g glucans/day). The glucan extracts were especially prepared for this study by Innerlife (Venlo, the Netherlands) and the procedure is described by Volman et al. (2009) . Briefly, semi-purified polysaccharides were obtained from fruiting body material by hot water extraction followed by ethanol precipitation as described before . A final solution was made in phosphatebuffered saline at 900 mg/ml, which was then heated for 1 h at 100 1C and stored at 4 1C. a-(1-4) Glucan was obtained from Agaricus bisporus stipes by passage of the polysaccharide extract over a DEAE-cellulose column. The colorless nonbinding polysaccharide has an MW 4200 kDa, which can be completely degraded by a-amylase, and is characterized as an a-glucan. We later discovered that the extract does not bind to a C18 column and runs as a single peak giving 100% recovery (unpublished results). The polysaccharide fraction of the Agaricus bisporus extract consisted 90% of a-(1-4) glucan. In addition, approximately 10% of the polysaccharide Values are means ± s.d.
Immune-modulating effect of A. bisporus a-glucans JJ Volman et al complexes with polyphenolic compound and elute from a DEAE cellulose column at 0.25-0.40 M NaCl. The general composition of hot water mushrooms extract was published earlier and showed a presence of approximately 5% (W/W) polyphenols in the mixtures, whereas their protein content was usually less than 2%. Therefore, the a-glucan extract could be considered as 'highly purified'. The a-glucan extracts were subsequently incorporated into the fruit juices. The fruit juice was a blend containing 10 different fruits and contained per 100 ml 47.2 kcal, 11.3 g carbohydrate, 0.01 g fat and 0.47 g protein. During the study, subjects recorded in diaries about their illnesses, medication used, alcohol consumption, any deviations to the study protocol and any side effects experienced.
At the end of the run-in period (week 2) and the end of the intervention period (week 7) blood was sampled after an overnight fast of at least 10 h. Subjects were not allowed to consume alcohol 24 h before blood sampling and were not allowed to smoke the morning before blood sampling. There were two smokers in both the control and the a-glucan group. Blood was sampled in endotoxin-free heparinized tubes and serum tubes (Becton Dickinson Vacutainer Systems, Franklin Lakes, NJ, USA) for PBMC isolation and clinical chemistry, respectively.
PBMC stimulation
To examine ex vivo cytokine production by PBMCs, cells were isolated from 16 ml heparinized whole blood by means of gradient centrifugation under sterile conditions using Lymphoprep according to the manufacturers' instructions (Nycomed Ltd, Birmingham, UK). After isolation, PBMCs were immediately plated in 24-well flat-bottom culture plates.
For evaluation of IL-1b, IL-6 and TNFa production, cells were diluted to 2.5 Â 10 6 cells per ml and seeded. Cells were mixed with LPS (Escherichia Coli 055:B5, Sigma, St Louis, MO, USA) or polymixin B (Sigma) to a final concentration of 10 ng/ml. Polymixin B was used as a negative control as it binds to LPS. Cells were cultured in RPMI-1640 with HEPES and L-glutamine (Invitrogen, Breda, The Netherlands) supplemented with 1% heat-inactivated human serum pool, 1% penicillin streptomycin (Invitrogen) and 1% sodium pyruvate (Invitrogen). The cells were incubated for 4 h at 37 1C in a 5% CO 2 -humidified atmosphere. After incubation, the culture media were aspirated and centrifuged at 1500 r.p.m. for 5 min to obtain cell-free media, which were stored at À80 1C until further analysis. For analysis of Th1/Th2 cytokine production, PBMCs were diluted to 1 Â 10 6 cells per ml and seeded in 24-well flat-bottom culture plates. Next, 50 mg/ml PHA (Roche, Mannheim, Germany) was added to initiate proliferation of the CD4 þ T cells. Medium was aspirated after 52 h proliferation and centrifuged at 14 000 r.p.m. for 2 min. Culture media were stored at À80 1C until further analysis for cytokines.
Cytokine analysis IL-1b, IL-6 and TNFa concentrations in supernatant of 4 hstimulated PBMC were assessed by commercially available MSD multiplex ELISAs (MSD, Gaithersburgh, MD, USA), as described by the manufacturers. Also IL-2, IL-4, IL-5, IL-12, IL-13, IL-17 and IFN-g concentrations were analyzed in supernatant of 52 h-stimulated PBMC, by custom panel MSD multiplex ELISAs (MSD).
Clinical chemistry
Serum samples collected at the end of the run-in and intervention period were analyzed to determine parameters reflecting kidney and liver function (creatinine, alanine transaminase, aspartate aminotransferase, g-glutamyl transpeptidase, alkaline phosphatise and total bilirubin) by routine procedures.
Statistics
Normality was tested by the Shapiro-Wilk test. Baseline characteristics are presented as means ± s.d. and were analyzed for statistical differences by an independent samples t-test. The baseline cytokine concentrations were tested by the non-parametric Mann-Whitney test, as these were not normally distributed. For each subject, responses in amounts of cytokines produced were calculated as the change between the concentration at the end of the run-in period (week 2) and those at the end of the intervention period (week 7). The same was done for clinical chemistry parameters. Cytokine concentrations and clinical chemistry parameters are presented as medians with ranges. As the changes in concentrations of the cytokines, liver and kidney function parameters were not normally distributed, the differences in changes were tested by the non-parametric Mann-Whitney test. Differences were considered statistically different at Po0.05. All statistical analyses were performed using SPSS 15.0 (SPSS, Chicago, IL, USA).
Results
Effects of a-glucans from A. bisporus on cytokine production by LPS-stimulated PBMCs Concentrations of the cytokines IL-1b, IL-6 and TNFa produced by LPS-stimulated PBMCs both at the end of the run-in period as well as at the end of the experimental period were analyzed (Table 2) . At baseline there were no differences between both groups. The median change in TNFa production by PBMCs was 69% lower in the A. bisporus group (249 pg/ml, range À656 to 2025 pg/ml) as compared with the change in the control group (792 pg/ml, range À1071 to 1675 pg/ml; P ¼ 0.017). Individual changes in TNFa production by PBMC are shown in Figure 1 . No statistical differences were found for the changes in IL-1b and IL-6 between both groups. All polymixin B controls were negative (data not shown).
Effects of a-glucan rich fractions from A. bisporus on cytokine production by PHA-stimulated PBMCs The effects of the consuming a-glucan enriched drinks on cytokine production by PHA-stimulated PBMCs as compared to the effects of PBMCs isolated from the control group are shown in Table 3 . At baseline there were no differences between both groups. The change in IL-12 production after the intervention period showed a trend towards a decreased production after A. bisporus consumption (À10 pg/ml, range À79 to 37 pg/ml) as compared with control drinks (4 pg/ml, range À51 to 53 pg/ml; P ¼ 0.059). Also the production of IL-10 showed a trend towards a lower production after A. bisporus consumption (À159pg/ml, range À1454 to 918 pg/ml) as compared with the control group (56 pg/ml, range À644 to 1343 pg/ml; P ¼ 0.053). There was no effect of the a-glucan fraction from A. bisporus on the production of IFNg, IL-2, IL-13, IL-4 and IL-17 of PHA-stimulated PBMCs (P-values for diet effects: IFNg, P ¼ 0.451; IL-2, P ¼ 0.274; IL-13, P ¼ 0.961; IL-4, P ¼ 0.791 and IL-17, P ¼ 0.173) ( Table 3) .
Effects of a-glucan-enriched drinks on kidney and liver function parameters Parameters reflecting kidney and liver function were determined in serum samples from all subjects at the end of the run-in period as well as at the end of the intervention period. Median creatinine, alanine transaminase, aspartate aminotransferase, g-glutamyl transpeptidase, alkaline phosphatise Figure 1 Effects of a-glucan consumption (5 g/day) from A. bisporus on TNFa concentration after ex vivo LPS stimulation of PBMCs. PBMCs were stimulated for 4 h with 10 ng/ml LPS from E. Coli 055:B5. *P ¼ 0.017 vs control Immune-modulating effect of A. bisporus a-glucans JJ Volman et al and total bilirubin concentrations were all within normal ranges at both occasions (Table 4) . Moreover, the changes were not different between the intervention and control groups, except for creatinine, which showed a trend towards a lower concentration in the A. bisporus group (P ¼ 0.081).
Discussion
In this study, we have evaluated the effects of fruit juice enriched with the a-glucan fraction from A. bisporus on cytokine production patterns by LPS-and PHA-stimulated PBMCs. The use of fungal b-glucans, and perhaps also of a-glucans, has been proposed to skew the Th1-Th2 balance into the Th1-direction. This would be useful to ameliorate Th2-skewed allergies, and on the other hand promoting Th1 responses in depressed states of immunity. In contrast to the expectation, here we show no skewing into the Th1 direction by A. bisporus-derived a-glucans. On the contrary, we found that the consumption of a-glucans from A. bisporus rather tended to lower the production of the Th1 cytokine IL-12 as compared with control in PHA-induced proliferating PBMCs. IL-12 is produced by monocytes/macrophages and, besides stimulating NK cells, it has a crucial role in promoting the differentiation of naive T-cells to a Th1 phenotype. The decreased level of IL-12 after A. bisporus is in line with the fact that there was no change in the concentration of the Th1 cytokine IFNg. In contrast, in mice an elevated IFNg production by splenocytes after dietary supplementation with A. bisporus has been reported (Wu et al., 2007) . Moreover, the consumption of an a-glucan protein complex (94.3% sugar) from another fungal source (Tricholoma matsutake) recovered the stress-induced decrease in IL-12 serum concentration in mice (Hoshi et al., 2005) . This suggests that a-glucans could have in vivo effects on Th1 cytokines, at least in mice. Besides IL-12, also the production of IL-10 showed a trend towards decreased production after A. bisporus consumption as compared with control drinks. In contrast, Yu et al. (2009) found that oral administration of A. bisporus had no effect on ex vivo IL-10 concentrations in mice. Moreover, Wu et al. (2007) showed that dietary supplementation of dried A. bisporus powder did not affect IL-10 production by mice splenocytes. Therefore, the observation that IL-10 tended to be lower in the A. bisporus group is more or less in line with other studies. Finally, the a-glucan fractions from A. bisporus did not affect the production of IL-2, IL-13, IL-4 and IL-17.
Besides, the immune-modulating effect of A. bisporus a-glucan rich fractions on the Th1-Th2 balance of cytokines produced by PBMCs, we also evaluated the behavior of PBMC towards LPS. We showed that a-glucans from A. bisporus reduced TNFa production by LPS-stimulated PBMCs as compared with control. This effect is in contrast to our in vitro findings in which TNFa secretion by bone marrow-derived macrophages from mice was increased by A. bisporus a-glucan extract. This in vitro finding was in line with the elevated TNFa and IL-12 secretion by mice macrophages and dendritic cells treated with a-glucans from Pseudallescheria boydii in vitro (Bittencourt et al., 2006) . However, our current finding suggests that in the in vivo situation, a-glucans have lost their efficacy to stimulate the response to LPS.
There is a vast amount of data from in vitro and animal studies showing immune-stimulating effects of mushrooms. Comparing our data with that of others, who showed immune-stimulating effects, is difficult because earlier studies have used whole mushroom extracts (Wu et al., 2007; Ren et al., 2008) , while we have specifically evaluated the effect of the a-glucan rich polysaccharide fraction from the mushrooms, which might have contributed to observed differences in results. On the other hand, by comparing results of studies evaluating effects of whole mushroom extracts with our data may provide further insight in effective components as we now know that in vivo, a-glucans are not effective in promoting Th1 responses by PHAstimulated PBMCs, as well as stimulating LPS-induced cytokine production by PBMCs.
The question remains why the A. bisporus a-glucan rich fractions did not stimulate human PBMC behavior in Immune-modulating effect of A. bisporus a-glucans JJ Volman et al response to ex vivo LPS and PHA treatments, whereas there are suggestions from the literature, not only from cell experiments but also from animal studies that a-glucans have immune-stimulating capacity. First, the immunological response of mice and humans differs (Mestas and Hughes, 2004) , so the use of different experimental models may have influenced the outcomes. There are several examples in the literature of treatments that were effective in mice, whereas they failed to show effects in humans. For example, IFNg has been reported to exacerbate disease in an experimental autoimmune model for multiple sclerosis (MS) in mice (Heremans et al., 1996) , whereas human clinical trials showed a beneficial effect (Panitch et al., 1987) . In addition, more knowledge regarding intestinal a-glucan handling is essential to explain the lack of effect. When the a-glucans are orally administered, the question arises whether they are absorbed in the gastrointestinal tract and reach the PBMCs as such. For b-glucans it has been shown that mice intestinal macrophages (Hong et al., 2004) and enterocytes (presumably Microfold (M)-cells) (Saegusa et al., 2004; Rice et al., 2005) can take up and distribute them after oral intake. Whether this also holds for a-glucans needs to be determined. On the other hand, it might be that absorption of the a-glucans is not crucial to exert their effects since intestinal dendritic cells sense the intestinal lumen and by this deliver fragments of the a-glucans to the underlying cells of the intestinal immune system (Rescigno et al., 2001; Niess and Reinecker, 2005) . Consequently, activated intestinal lymphocytes may migrate to the mesenteric lymph nodes and come back via lymphatic vessels and blood to intestinal lamina propria. Hypothetically, as food antigen-specific T cells have been reported in peripheral blood (Kantele et al., 1999; Eigenmann, 2002) , the isolated PBMCs might contain a-glucan-activated lymphocytes that normally would return to the intestine. Nevertheless, we did not observe a clear effect on cytokine production by isolated PBMCs, suggesting that if lymphocytes are activated by the mushroom a-glucans, these effects remained local. However, we only analyzed effects in circulating PBMCs and we did not evaluate the intestinal immune response as such. Besides the idea that the immune-modulating effects only occurred locally, a final explanation for the lack of a clear immunemodulating effect of the A. bisporus derived a-glucans might relate to the comparable structure with amylose. In vivo these compounds can be digested by a-amylases present in saliva and pancreatic juice. Furthermore, we investigated the effect of 90% pure a-glucan extract, which does not rule out that other components of A. bisporus, like b-glucans, can have an immune-stimulating effect. They were, however, only in minor fractions present in our drinks. Safety of the mushroom a-glucan-enriched drinks is important as three cases of cancer patients who consumed extracts from another edible mushroom (Agaricus blazei) for several days to months during conventional chemotherapy reported severe hepatic damage (Mukai et al., 2006) . We found no effects of the A. bisporus a-glucan drinks on parameters reflecting liver and kidney function. We even observed a trend towards a lower concentration of creatinine in the A. bisporus group as compared with the control group. Therefore we conclude that in this population of healthy subjects with slightly elevated serum total cholesterol concentrations, consumption of 5 g (dry matter) of an a-glucan rich polysaccharide fraction does not affect liver or kidney function, at least within this 5-week follow-up period.
In summary, this is the first large-scale placebo controlled intervention study in humans to evaluate the immunemodulating effects of a-glucan from A. bisporus. In contrast to the expected immune stimulation into a Th1 direction, here we showed no obvious Th1-Th2 skewing effects of a-glucans from A. bisporus by PHA-stimulated PBMCs as compared with the control group. Furthermore, we found that the consumption of a-glucans from A. bisporus lowers TNFa production by LPS-stimulated PBMCs as compared with the control group. The absence of strong immune modulating effect on PBMCs might relate to the comparable structure of a-glucan with amylose. It is known that these compounds can be digested in vivo by a-amylases that are present in saliva and pancreatic juice. Therefore, our current finding suggests that in the in vivo situation, a-glucans have lost their efficacy to stimulate the systemic immune response observed in our in vitro mouse model. Furthermore, it cannot be excluded that a-glucans have only local effects in the intestine, which are not reflected in systemic PBMC behavior.
